Autor: |
Morris DR; Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX.; School of Public & Population Health, The University of Texas Medical Branch, Galveston, TX.; Department of Pediatrics, The University of Texas Medical Branch, Galveston, TX., Qu Y; Department of Pediatrics, The University of Texas Medical Branch, Galveston, TX., Thomason KS; Department of Pediatrics, The University of Texas Medical Branch, Galveston, TX., de Mello AH; Department of Pediatrics, The University of Texas Medical Branch, Galveston, TX., Preble R; John Sealy School of Medicine, The University of Texas Medical Branch, Galveston, TX., Menachery VD; Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX., Casola A; Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX.; Department of Pediatrics, The University of Texas Medical Branch, Galveston, TX., Garofalo RP; Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX.; Department of Pediatrics, The University of Texas Medical Branch, Galveston, TX. |
Abstrakt: |
RSV and SARS-CoV-2 are prone to co-infection with other respiratory viruses. In this study, we use RSV/SARS-CoV-2 co-infection to evaluate changes to clinical disease and viral replication in vivo. To consider the severity of RSV infection, effect of sequential infection, and the impact of infection timing, mice were co-infected with varying doses and timing. Compared with a single infection of RSV or SARS-CoV-2, the co-infection of RSV/SARS-CoV-2 and the primary infection of RSV followed by SARS-CoV-2 results in protection from SARS-CoV-2-induced clinical disease and reduces SARS-CoV-2 replication. Co-infection also augmented RSV replication at early timepoints with only the low dose. Additionally, the sequential infection of RSV followed by SARS-CoV-2 led to improved RSV clearance regardless of viral load. However, SARS-CoV-2 infection followed by RSV results in enhanced SARS-CoV-2-induced disease while protecting from RSV-induced disease. SARS-CoV-2/RSV sequential infection also reduced RSV replication in the lung tissue, regardless of viral load. Collectively, these data suggest that RSV and SARS-CoV-2 co-infection may afford protection from or enhancement of disease based on variation in infection timing, viral infection order, and/or viral dose. In the pediatric population, understanding these infection dynamics will be critical to treat patients and mitigate disease outcomes. |